R M Gulick

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi request reprint Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
    R M Gulick
    Department of Medicine, New York University School of Medicine, New York, USA
    JAMA 280:35-41. 1998
  2. ncbi request reprint 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
    R M Gulick
    Weill Medical College of Cornell University, New York, New York, USA
    Ann Intern Med 133:35-9. 2000
  3. ncbi request reprint The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
    J J Eron
    Department of Medicine, Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599 7030, USA
    J Infect Dis 181:1622-8. 2000
  4. ncbi request reprint Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359
    R M Gulick
    Cornell Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Dept of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Infect Dis 182:1375-84. 2000
  5. ncbi request reprint Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373
    R M Gulick
    Weill Medical College of Cornell University and New York University School of Medicine, Cornell Clinical Trials Unit, New York, NY 10021, USA
    J Infect Dis 183:715-21. 2001
  6. ncbi request reprint Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease
    B H Lerner
    Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Ann Intern Med 129:573-8. 1998
  7. ncbi request reprint New antiretroviral drugs
    R M Gulick
    Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10024, USA
    Clin Microbiol Infect 9:186-93. 2003

Detail Information

Publications7

  1. ncbi request reprint Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
    R M Gulick
    Department of Medicine, New York University School of Medicine, New York, USA
    JAMA 280:35-41. 1998
    ..Combination antiretroviral therapy can markedly suppress human immunodeficiency virus (HIV) replication but the duration of HIV suppression varies among patients...
  2. ncbi request reprint 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
    R M Gulick
    Weill Medical College of Cornell University, New York, New York, USA
    Ann Intern Med 133:35-9. 2000
    ..Antiretroviral regimens containing HIV protease inhibitors suppress viremia in HIV-infected patients, but the durability of this effect is not known...
  3. ncbi request reprint The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
    J J Eron
    Department of Medicine, Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599 7030, USA
    J Infect Dis 181:1622-8. 2000
    ..Persistent replication of HIV in the genital tract may have implications for the selection of resistant virus and sexual transmission of HIV-1...
  4. ncbi request reprint Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359
    R M Gulick
    Cornell Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Dept of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Infect Dis 182:1375-84. 2000
    ..18%; P=.002). Overall, one-third of patients who experienced virologic failure on an indinavir-containing regimen suppressed virus load levels while they were taking a new salvage regimen...
  5. ncbi request reprint Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373
    R M Gulick
    Weill Medical College of Cornell University and New York University School of Medicine, Cornell Clinical Trials Unit, New York, NY 10021, USA
    J Infect Dis 183:715-21. 2001
    ..7; P=.0012). In this study, most subjects who had taken amprenavir-based regimens and who changed to a 4-drug regimen achieved subsequent durable virologic suppression...
  6. ncbi request reprint Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease
    B H Lerner
    Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Ann Intern Med 129:573-8. 1998
    ..Encouraging the active participation of HIV-positive persons in their own treatment will help avoid judgmental and inaccurate assessments of patient behavior and may help patients take medications more successfully...
  7. ncbi request reprint New antiretroviral drugs
    R M Gulick
    Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10024, USA
    Clin Microbiol Infect 9:186-93. 2003
    ..Investigational HIV integrase inhibitors include S-1360. Continued progress in the treatment of HIV disease will result from the development of new antiretroviral drugs...